Skip to main content

Drug Interactions between celecoxib and fosphenytoin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

fosphenytoin celecoxib

Applies to: fosphenytoin and celecoxib

MONITOR: Coadministration with inducers of CYP450 2C9 may decrease the plasma concentrations of celecoxib, which is primarily metabolized by the isoenzyme. When a single 200 mg dose of celecoxib was administered to 12 healthy volunteers following pretreatment with the moderate CYP450 2C9 inducer rifampin 600 mg once daily for 5 days, celecoxib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 56% and 64%, respectively, while clearance increased by 185%. Reduced efficacy of celecoxib may occur.

MANAGEMENT: The potential for diminished pharmacologic effects of celecoxib should be considered during coadministration with CYP450 2C9 inducers. Dose adjustments or alternative treatments may be required if an interaction is suspected.

References (2)
  1. Jayasagar G, Krishna Kumar M, Chandrasekhar K, Madhusudan Rao Y (2003) "Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers." Drug Metabol Drug Interact, 19, p. 287-95
  2. (2022) "Product Information. Seglentis (celecoxib-tramadol)." Kowa Pharmaceuticals America (formerly ProEthic)

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer